STOCK TITAN

Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at two upcoming healthcare conferences. Live webcasts and replays of the presentations will be available on the investor relations section of the corporate website.

21st Annual Needham Virtual Healthcare Conference
Tuesday, April 12, 2022
10:15 a.m. ET

BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022
4:00 p.m. ET

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.

Cardiovascular Systems, Inc.

Jack Nielsen

Vice President, Investor Relations

& Corporate Communications

(651) 202-4919

j.nielsen@csi360.com

Source: Cardiovascular Systems, Inc.

CSII

NASDAQ:CSII

CSII Rankings

CSII Latest News

CSII Stock Data

843.96M
40.46M
3.23%
89.65%
4.12%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
St Paul

About CSII

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.